Roche, which already sells pegylated interferon (Pegasys) and ribavirin (Copegus), announced in May that in a small early-stage trial its polymerase inhibitor was effective in significantly reducing the viral load.
Viral loads of the patients remained stable or decreased during the nine month trial - and one subject showed a sustained dramatic decrease in viral load.